WO2013164102A1 - Process for preparation of ixabepilone and intermediates useful in said process. - Google Patents

Process for preparation of ixabepilone and intermediates useful in said process. Download PDF

Info

Publication number
WO2013164102A1
WO2013164102A1 PCT/EP2013/050463 EP2013050463W WO2013164102A1 WO 2013164102 A1 WO2013164102 A1 WO 2013164102A1 EP 2013050463 W EP2013050463 W EP 2013050463W WO 2013164102 A1 WO2013164102 A1 WO 2013164102A1
Authority
WO
WIPO (PCT)
Prior art keywords
compound
formula
group
straight
ixabepilone
Prior art date
Application number
PCT/EP2013/050463
Other languages
French (fr)
Inventor
Audun Heggelund
Vidar BJØRNSTAD
Original Assignee
Xellia Pharmaceuticals Aps
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Xellia Pharmaceuticals Aps filed Critical Xellia Pharmaceuticals Aps
Publication of WO2013164102A1 publication Critical patent/WO2013164102A1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems
    • C07D491/044—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring

Definitions

  • the present invention relates to a process for the preparation of Ixabepilone and also to novel intermediates useful in the process according to the present invention.
  • Ixabepilone is an anti cancer agent acting as a microtubule inhibitor, and which in particular are efficient in the treatment of cancer not reacting to other anti cancer agents, such as e.g. paclitaxel.
  • Ixabepilone is marketed under the trade name Ixempra® and are approved for the treatment of aggressive metastatic or locally advanced breast cancer which not responding to the current prevailing chemotherapies.
  • Ixabepilone known under the CAS no. 219989-84-1 has the following structure:
  • Ixabepilone may be prepared from a starting material named Epothilone B having the structural formula:
  • Epothilone B Ixabepilone as a compound and different aspects regarding the compound are described in the USRE4191 1 , US 6,365,749 and USRE39356. Summary of invention
  • the present provides a process for the preparation of Ixabepilone having the formula 5 :
  • Ri and R 2 are independently selected from the group consisting of H, a straight or branched alkyl group or a straight or branched acyl group to form Ixabepilone.
  • a process for the preparation of Ixabepilone comprising the steps of reducing a compound of formula 4, wherein X is N; and Ri is H and R 2 is Ci_s alkyl or Ci_s acyl.
  • X is N; and Ri is H and R 2 is Ci_ 3 alkyl or Ci_ 3 acyl.
  • X is N; and Ri is H and R 2 is acetyl.
  • a process wherein the starting material of formula 4 of step a) is prepared by: i) reacting Epothilone B with a nucleophile of formula NH 2 -XRiR 2 , wherein X, Ri and R 2 is as defined above, in order to form a compound of formula 2
  • the ring closure step ii) is performed by reacting the compound of formula 2 with an activation system or activation agent.
  • the said activation system or activation agent is selected from the group consisting of EDC/HOBt,
  • EDC/pentafluorophenol, pentafluorophenyl diphenylphosphinate, pentafluorophenyl diphenylphosphinate and diphenyl phosphoryl azide According to another aspect of the present invention, the conversion of Epothilone B to the compound of formula 4 is performed in a one-pot step.
  • the reacting of Epothilone B with a nucleophile is performed in the presence of a palladium catalyst.
  • the present invention furthermore provides a novel compound of formula 4
  • X is N
  • Ri and R 2 are independently selected from the group consisting of H, a straight or branched alkyl group or a straight or branched acyl group.
  • a compound of formula 4 is provided wherein X is N; and Ri is H and R 2 is Ci_s alkyl or Ci_s acyl.
  • a compound of formula 4 is provided, wherein X is N; and Ri is H and R 2 is Ci_ 3 alkyl or Ci_ 3 acyl.
  • a compound of formula 4 is provided, wherein X is N; and Ri is H and R 2 is acetyl.
  • the present invention furthermore provides a process for the preparation of compound 4, wherein said process comprises the steps of activating the carboxylic acid of a compound of formula 2
  • Ri and R 2 are independently selected from the group consisting of H, a straight or branched alkyl group or a straight or branched acyl group with an activation system or activation agent, such as e.g. EDC/HOBt, EDC/ pentafluorophenyl, pentafluorophenyl diphenylphosphinate and pentafluorophenyl diphenylphosphinate, diphenyl phosphoryl azide followed by ringclosure.
  • EDC/HOBt EDC/ pentafluorophenyl, pentafluorophenyl diphenylphosphinate and pentafluorophenyl diphenylphosphinate, diphenyl phosphoryl azide followed by ringclosure.
  • Ri and R 2 are independently selected from the group consisting of H, a straight or branched alkyl group or a straight or branched acyl group by a one pot ring closure and reduction step.
  • the ring closure of the above process is performed by activating the carboxylic acid group of the compound of formula 2 using diphenylphosphoryl azide as an activation agent.
  • Ixabepilone may be prepared by reduction of a compound of formula 4
  • Ri and R 2 is independently selected from the group consisting of H, a straight or branched alkyl group or a straight or branched acyl group.
  • the compound of formula 4 may be prepared by the ring opening of Epothilone B to form a compound of formula 2:
  • Ixabepilone is prepared according to the steps of reactions illustrated in Scheme 1.
  • the compound H 2 N-XRiR 2 includes nitrogen nucleophiles wherein X denotes the heteroatom N.
  • the heteroatom X carries two entities Ri and R 2 according to its preferred valency.
  • Ri or R 2 may independently be selected from the group consisting of H, a straight or branched alkyl group or a straight or branched acyl group, wherein said alkyl or acyl may be substituted or un- substituted.
  • Other examples of nitrogen nucleophiles that may be used according to the present invention are the free forms of hydrazine, which optionally may be substituted, e.g. N-alkylhydrazines, and N-acylhydrazines, e.g. acethydrazide (CH3CONH-NH 2 ).
  • Ri or R 2 are selected from the group consisting of Ci_8 alkyl or Ci_s acyl. According to anther embodiment, Ri and R 2 is independently selected from the group consisting of Ci_ 3 alkyl or Ci_ 3 acyl. According to a preferred embodiment, Ri is H and R 2 is acetyl.
  • Epothilone B (1) is treated with the nitrogen nucleophile H 2 N- XR 1 R 2 in the presence of a palladium catalyst.
  • the substrate undergoes ring- opening and formation of the structure 2 as an intermediate.
  • Activation of the carboxylic acid group with a suitable activation system affords the activated compound 3.
  • the term "Act" in Scheme 1 refers to any group that activates the carboxylic acid group for attack from a nucleophile, and is herein named “activation agents” or “activation systems”. The skilled person will acknowledge that a number of well known activation agents or activation systems may be used in order to activate carboxylic acid group of the intermediate 2 in order to effect a ring closure.
  • one suitable activation system is the EDC/HOBt system where EDC stands for N-(3-dimethylaminopropyl)-N'- ethylcarbodiimide hydrochloride and HOBt stands for 1 -hydro xybenzotriazole hydrate.
  • Another suitable activation system is EDC/pentafluorophenol.
  • Yet another example of a suitable activation agent is pentafluorophenyl diphenylphosphinate.
  • Yet another example of a suitable activation agent is diphenyl phosphoryl azide.
  • Ring closing provides the intermediate structure 4, while reductive cleavage of the N-X bond releases the target Ixabepilone (5).
  • the reductive cleavage may be obtained by various reduction agents.
  • the compound 4 may be treated with powdered Zn in acetic acid, resulting in cleavage of the N-N bond and formation of Ixabepilone (5). Examples
  • Example 2 Activation of compound 2 and ring closure (I) in order to form compound 4 in accordance with scheme 1
  • Example 3 Activation of compound 2 and ring closure (II) in order to form compound 4 in accordance with scheme 1.
  • reaction mixture was stirred under nitrogen at room temperature for 30 min. 2 eq DIPEA was added and the mixture stirred for an additional 30 min. before the addition of 0, 1 eq DMAP. The mixture was then stirred for 2 days, diluted with ethyl acetate and washed with water and then with brine solution.
  • Example 4 Activation of compound 2 and ring closure (III) in order to form compound 4 in accordance with scheme 1.
  • pentafluorophenyl diphenylphosphinate was used as activation agent.
  • Ixabepilone was formed in a one pot reaction by activation of the compound 2 (formula II) by activation using diphenyl phosphoryl azide as activation agent, resulting in the formation of compound 4 of scheme 1 , followed by spontaneous formation of Ixabepilone:

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

The present invention describes a process for preparation of Ixabepilone and intermediates useful in said process.

Description

Process for preparation of Ixabepilone and intermediates useful in said process.
Field of invention
The present invention relates to a process for the preparation of Ixabepilone and also to novel intermediates useful in the process according to the present invention.
Ixabepilone is an anti cancer agent acting as a microtubule inhibitor, and which in particular are efficient in the treatment of cancer not reacting to other anti cancer agents, such as e.g. paclitaxel. Ixabepilone is marketed under the trade name Ixempra® and are approved for the treatment of aggressive metastatic or locally advanced breast cancer which not responding to the current prevailing chemotherapies.
Ixabepilone known under the CAS no. 219989-84-1 has the following structure:
Figure imgf000002_0001
Ixabepilone
Ixabepilone may be prepared from a starting material named Epothilone B having the structural formula:
Figure imgf000002_0002
Epothilone B Ixabepilone as a compound and different aspects regarding the compound are described in the USRE4191 1 , US 6,365,749 and USRE39356. Summary of invention
The present provides a process for the preparation of Ixabepilone having the formula 5 :
Figure imgf000003_0001
comprising the step of:
reducing a compound of formula
Figure imgf000003_0002
4
wherein X is N, Ri and R2 are independently selected from the group consisting of H, a straight or branched alkyl group or a straight or branched acyl group to form Ixabepilone.
According to one aspect of the present invention, a process is provided for the preparation of Ixabepilone comprising the steps of reducing a compound of formula 4, wherein X is N; and Ri is H and R2 is Ci_s alkyl or Ci_s acyl. According to another aspect, X is N; and Ri is H and R2 is Ci_3 alkyl or Ci_3 acyl. According to yet another aspect, X is N; and Ri is H and R2 is acetyl.
According to another aspect of the present invention, a process is provided, wherein the starting material of formula 4 of step a) is prepared by: i) reacting Epothilone B with a nucleophile of formula NH2-XRiR2, wherein X, Ri and R2 is as defined above, in order to form a compound of formula 2
Figure imgf000004_0001
2
ii) ringclosure of the compound of formula II in order to form the compound of formula 4.
According to a further aspect of the above invention, the ring closure step ii) is performed by reacting the compound of formula 2 with an activation system or activation agent. According to yet a further aspect of the present invention, the said activation system or activation agent is selected from the group consisting of EDC/HOBt,
EDC/pentafluorophenol, pentafluorophenyl diphenylphosphinate, pentafluorophenyl diphenylphosphinate and diphenyl phosphoryl azide. According to another aspect of the present invention, the conversion of Epothilone B to the compound of formula 4 is performed in a one-pot step.
According to yet another aspect of the present invention, the reacting of Epothilone B with a nucleophile is performed in the presence of a palladium catalyst.
The present invention furthermore provides a novel compound of formula 4
Figure imgf000004_0002
wherein X is N, Ri and R2 are independently selected from the group consisting of H, a straight or branched alkyl group or a straight or branched acyl group. According to one embodiment of the present invention, a compound of formula 4 is provided wherein X is N; and Ri is H and R2 is Ci_s alkyl or Ci_s acyl. According to another embodiment, a compound of formula 4is provided, wherein X is N; and Ri is H and R2 is Ci_3 alkyl or Ci_3 acyl. According to yet another aspect of the present invention, a compound of formula 4 is provided, wherein X is N; and Ri is H and R2 is acetyl.
The present invention furthermore provides a process for the preparation of compound 4, wherein said process comprises the steps of activating the carboxylic acid of a compound of formula 2
Figure imgf000005_0001
2
wherein X is N, Ri and R2 are independently selected from the group consisting of H, a straight or branched alkyl group or a straight or branched acyl group with an activation system or activation agent, such as e.g. EDC/HOBt, EDC/ pentafluorophenyl, pentafluorophenyl diphenylphosphinate and pentafluorophenyl diphenylphosphinate, diphenyl phosphoryl azide followed by ringclosure.
Finally, a process is provided for the preparation of Ixabepilone of the formula 5:
Figure imgf000005_0002
2 wherein X is N, Ri and R2 are independently selected from the group consisting of H, a straight or branched alkyl group or a straight or branched acyl group by a one pot ring closure and reduction step.
According to aspect, the ring closure of the above process is performed by activating the carboxylic acid group of the compound of formula 2 using diphenylphosphoryl azide as an activation agent.
Detailed description of the invention.
The present method is further illustrated by the following detailed description of the present invention.
According to the present invention, Ixabepilone may be prepared by reduction of a compound of formula 4
Figure imgf000006_0001
wherein is X is N, and Ri and R2 is independently selected from the group consisting of H, a straight or branched alkyl group or a straight or branched acyl group. The compound of formula 4, may be prepared by the ring opening of Epothilone B to form a compound of formula 2:
Figure imgf000006_0002
2
using a nitrogen nucleophile, followed by the conversion of the compound formula 2 to the compound of formula 4. According to one embodiment of the present invention, Ixabepilone is prepared according to the steps of reactions illustrated in Scheme 1.
Figure imgf000007_0001
Activation
of acid
Figure imgf000007_0002
Reduction
Figure imgf000007_0003
Ixabepilone
Scheme 1
The compound H2N-XRiR2 includes nitrogen nucleophiles wherein X denotes the heteroatom N. The heteroatom X carries two entities Ri and R2 according to its preferred valency. Ri or R2 may independently be selected from the group consisting of H, a straight or branched alkyl group or a straight or branched acyl group, wherein said alkyl or acyl may be substituted or un- substituted. Other examples of nitrogen nucleophiles that may be used according to the present invention are the free forms of hydrazine, which optionally may be substituted, e.g. N-alkylhydrazines, and N-acylhydrazines, e.g. acethydrazide (CH3CONH-NH2).
According to one embodiment, Ri or R2 are selected from the group consisting of Ci_8 alkyl or Ci_s acyl. According to anther embodiment, Ri and R2 is independently selected from the group consisting of Ci_3 alkyl or Ci_3 acyl. According to a preferred embodiment, Ri is H and R2 is acetyl.
The starting material Epothilone B (1) is treated with the nitrogen nucleophile H2N- XR1R2 in the presence of a palladium catalyst. The substrate undergoes ring- opening and formation of the structure 2 as an intermediate.
Activation of the carboxylic acid group with a suitable activation system affords the activated compound 3. The term "Act" in Scheme 1 refers to any group that activates the carboxylic acid group for attack from a nucleophile, and is herein named "activation agents" or "activation systems". The skilled person will acknowledge that a number of well known activation agents or activation systems may be used in order to activate carboxylic acid group of the intermediate 2 in order to effect a ring closure. For example, one suitable activation system is the EDC/HOBt system where EDC stands for N-(3-dimethylaminopropyl)-N'- ethylcarbodiimide hydrochloride and HOBt stands for 1 -hydro xybenzotriazole hydrate. Another suitable activation system is EDC/pentafluorophenol. Yet another example of a suitable activation agent is pentafluorophenyl diphenylphosphinate. Yet another example of a suitable activation agent is diphenyl phosphoryl azide.
Ring closing provides the intermediate structure 4, while reductive cleavage of the N-X bond releases the target Ixabepilone (5). The reductive cleavage may be obtained by various reduction agents. For example, the compound 4 may be treated with powdered Zn in acetic acid, resulting in cleavage of the N-N bond and formation of Ixabepilone (5). Examples
Example 1 - preparation of compound 2 according to Scheme 1
Figure imgf000009_0001
X = NHCOCH,
Nucleophile: NH2NHAc;
250 mg (1.0 eq) of Epothilone B and 10 ml degassed THF was added to a 50 ml round bottom flask under nitrogen atmosphere and stirred for 10 min. The mixture was cooled to 0°C and added 0.1 eq of allyl palladium chloride dimmer and 0.1 eq of Xantphos. Then, 1.5 eq acetic hydrazide dissolved in degassed THF was added during 15 min. The reaction mixture was allowed to reach room temperature and stirred for 3 h. Complete conversion was observed by TLC. The reaction mixture was diluted with ethyl acetate and washed with water followed by brine solution. The solvents were subsequently removed under vacuum to furnish the crude Epothilone B - acetic hydrazide adduct 2.
HPLC - MS [Column: Xbridge C-18 (50x3.0mm, 3,5um), Mobil phase: A; 5.0mM NH4OAc B; AcN (Gradient), Time/B%: 0.01/10 0.5/10 4/90 8/90, Flow: 0.8ml/Min, MS: ESI; positive mode] : Ret. time: 2.64 (82.5%), m/z: 582 (M+l , 100%).
Example 2: Activation of compound 2 and ring closure (I) in order to form compound 4 in accordance with scheme 1
Figure imgf000009_0002
Figure imgf000009_0003
In this example, a one-pot procedure starting from Epothilone B was used to form the compound 4 according to scheme 1 using EDC/HOBt as activation system:
To a 25 ml round bottom flask charged with 25 mg (1.0 eq) Epothilone B, 0.1 eq allyl palladium chloride dimmer, 0.1 eq Xantphos and 1.5 eq acetic hydrazide was added 1 ml degassed THF under nitrogen. The reaction mixture was stirred for 3 h at room temperature. Complete conversion was observed by TLC. Then 2.5 eq EDC and subsequently 1.1 eq HOBt was added and the reaction mixture stirred for 12 h at room temperature. The reaction mixture was diluted with ethyl acetate and washed with water followed by brine solution.
HPLC - MS [Column: Xbridge C-18 (50x3.0mm, 3,5um), Mobil phase: A; 5.0mM NH4OAc B; AcN (Gradient), Time/B%: 0.01/10 0.5/10 4/90 8/90, Flow: 0.8ml/Min, MS: ESI; positive mode] : Ret. time: 2.51 (14%), m/z: 564 (M+l , 100%).
Example 3: Activation of compound 2 and ring closure (II) in order to form compound 4 in accordance with scheme 1.
Figure imgf000010_0001
In this example, a one-pot procedure starting from Epothilone B was used to form the compound 4 according to scheme 1 , using EDC and pentafluorophenol (C6F5OH) as activation system:
To a 25 ml round bottom flask charged with 25 mg (1.0 eq) Epothilone B, 0.1 eq allyl palladium chloride dimmer, 0.05 eq Xantphos and 1.5 eq acetic hydrazide was added 1 ml degassed THF under nitrogen. The reaction mixture was stirred for 3 h at room temperature. Complete conversion was observed by TLC. The reaction mixture was diluted with ethyl acetate and washed with water followed by brine solution. The solvents were subsequently removed under vacuum and the crude mass dissolved in 2 ml THF. To this was added 2.5 eq EDC followed by 1.5 eq pentafluorophenol. Then the reaction mixture was stirred under nitrogen at room temperature for 30 min. 2 eq DIPEA was added and the mixture stirred for an additional 30 min. before the addition of 0, 1 eq DMAP. The mixture was then stirred for 2 days, diluted with ethyl acetate and washed with water and then with brine solution.
HPLC - MS [Column: Xbridge C-18 (50x3.0mm, 3.5um), Mobil phase: A; 5.0mM NH4OAc B; AcN (Gradient), Time/B%: 0.01/10 0.5/10 4/90 8/90, Flow: 0.8ml/Min, MS: ESI; positive mode] : Ret. time: 2.59 (72%), m/z: 564 (M+l , 100%).
Example 4 Activation of compound 2 and ring closure (III) in order to form compound 4 in accordance with scheme 1.
Figure imgf000011_0001
In this example, pentafluorophenyl diphenylphosphinate was used as activation agent.
Procedure starting from crude Epothilone B-acetic hydrazide adduct;
200 mg (1.0 eq) crude acetic hydrazide adduct was dissolved in 10 ml degassed DMF under nitrogen gas and cooled to 0° C. Then 3 eq DIPEA was added and subsequently 1 ,2 eq pentafluorophenyl diphenylphosphinate. The reaction mixture was left to reach room temperature and stirred for 12 h. Then the mixture was diluted with ethyl acetate and washed with water followed by brine solution.
HPLC - MS [Column: Xbridge C-18 (50x3.0mm, 3,5um), Mobil phase: A; 5.0mM NH4OAc B; AcN (Gradient), Time/B%: 0.01/10 0.5/10 4/90 8/90, Flow: 0.8ml/Min, MS: ESI; positive mode] : Ret. time: 2.65 (59%), m/z: 564 (M+l , 100%). Example 5 One pot reaction forming Ixabepilone from compound 2 according to scheme 1.
Figure imgf000012_0001
X = N HCOCH3
In this example, Ixabepilone was formed in a one pot reaction by activation of the compound 2 (formula II) by activation using diphenyl phosphoryl azide as activation agent, resulting in the formation of compound 4 of scheme 1 , followed by spontaneous formation of Ixabepilone:
100 mg (1.0 eq) crude Epothilone B - acetic hydrazide adduct was dissolved in 80 ml dry and degassed DMF and cooled to 0° C under nitrogen gas. Then 7.7 eq sodium bicarbonate and subsequently 4.0 eq diphenyl phosphoryl azide was added and stirring at 0° C maintained for 24 h. The reaction mixture was then diluted with 80 ml of cold phosphate buffer solution and extracted with ethyl acetate. Subsequent washing of the organic layer with cold 10% aqueous LiCl and drying with Na2S04 followed by concentration in vacuo then furnished the crude product. HPLC - MS [Column: Xbridge C-18 (50x3.0mm, 3,5um), Mobil phase: A; 5.0mM NH4OAc B; AcN (Gradient), Time/B%: 0.01/10 0.5/10 4/90 8/90, Flow: 0.8ml/Min, MS: ESI; positive mode] : Ret. time: 4.55 (43%), m/z: 507 (M+l , 7%).

Claims

1. A process for the preparation of Ixabepilone having the formula:
Figure imgf000013_0001
wherein
X is N,
Ri and R2 are independently selected from the group consisting of H, a straight or branched alkyl group or a straight or branched acyl group to form Ixabepilone 5.
A process according to claim 1 , wherein X is N; and Ri is H and R2 is Ci_s alkyl or Ci_s acyl.
A process according to claim 2, wherein X is N; and Ri is H and R2 is Ci_3 alkyl or Ci_3 acyl.
A process according to claim 3, wherein X is N; and Ri is H and R2 is acetyl.
A process according to claim 1 , wherein the starting material of formula 4 is prepared by: i) reacting Epothilone B with a nucleophile of formula NH2-XRiR2, wherein X, Ri and R2 are as defined in claim 1 , in order to form a compound of formula 2
Figure imgf000014_0001
2
ii) ringclosure of the compound of formula 2 in order to form the compound of formula 4.
6. A process according to claim 5, wherein the ring closure step ii) is performed by reacting the compound of formula 2 with an activation system or activation agent. 7. A process according to claim 6, wherein the activation system or activation agent is selected from the group consisting of EDC/HOBt,
EDC/pentafluorophenol, pentafluorophenyl diphenylphosphinate,
pentafluorophenyl diphenylphosphinate and diphenyl phosphoryl azide. 8. A process according to claim 7, wherein the conversion of Epothilone B to the compound of formula 4 is performed in a one-pot step.
Process according to any of the claims 5-8, wherein the reacting of Epothilone B with a nucleophile is performed in the presence of a palladium catalyst.
. A compound of formula 4
Figure imgf000014_0002
4
wherein
X is N, Ri and R2 are independently selected from the group consisting of H, a straight or branched alkyl group or a straight or branched acyl group.
1 1. Compound according to claim 10, wherein X is N; and Ri is H and R2 is Ci_s alkyl or Ci_s acyl.
12. Compound according to claim 1 1 , wherein X is N; and Ri is H and R2 is Ci_3 alkyl or Ci_3 acyl.
13. Compound according to claim 12, wherein X is N; and Ri is H and R2 is acetyl.
14. A process for the preparation of compound 4, wherein said process comprises the steps of activating the carboxylic acid of a compound of formula 2
Figure imgf000015_0001
2
wherein
X is N,
Ri and R2 are independently selected from the group consisting of H, a straight or branched alkyl group or a straight or branched acyl group with an activation system or activation agent, such as e.g. EDC/HOBt,
EDC/pentafluorophenyl, pentafluorophenyl diphenylphosphinate and pentafluorophenyl diphenylphosphinate, diphenyl phosphoryl azide followed by ringclosure.
15. A process for the preparation of Ixabepilone of the formula 5:
Figure imgf000015_0002
wherein the process consist of converting a compound of formula 2
Figure imgf000016_0001
wherein
X is N,
Ri and R2 is independently selected from the group consisting of H, straight or branched alkyl group or a straight or branched acyl group by one pot ring closure and reduction step.
16. Process according to claim 15, wherein the ring closure is performed by activating the carboxylic acid group of the compound of formula 2 using diphenylphosphoryl azide as an activation agent.
PCT/EP2013/050463 2012-04-30 2013-01-11 Process for preparation of ixabepilone and intermediates useful in said process. WO2013164102A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201261640170P 2012-04-30 2012-04-30
US61/640,170 2012-04-30

Publications (1)

Publication Number Publication Date
WO2013164102A1 true WO2013164102A1 (en) 2013-11-07

Family

ID=49514213

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2013/050463 WO2013164102A1 (en) 2012-04-30 2013-01-11 Process for preparation of ixabepilone and intermediates useful in said process.

Country Status (1)

Country Link
WO (1) WO2013164102A1 (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2015087351A3 (en) * 2013-12-11 2015-12-03 Msn Laboratories Private Limited Process for the preparation of (1s,3s,7s,10r,11s,12s,16r)-7,11-dihydroxy-8,8,10,12,16-pentamethyl-3-[(1e)-1-methyl-2-(2-methyl-4-thiazolyl)ethenyl]-17-oxa-4-azabicyclo[14.1.0]heptadecane-5,9-dione and intermediates thereof

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6365749B1 (en) 1997-12-04 2002-04-02 Bristol-Myers Squibb Company Process for the preparation of ring-opened epothilone intermediates which are useful for the preparation of epothilone analogs
USRE39356E1 (en) 2000-03-20 2006-10-17 Bristol-Myers Squibb Co. Process for the preparation of epothilone analogs
WO2011153221A1 (en) * 2010-06-01 2011-12-08 Plus Chemicals Sa Solid state forms of ixabepilone
WO2013008091A1 (en) * 2011-07-13 2013-01-17 Xellia Pharmaceuticals Aps Manufacturing of epothilone derivatives and the use thereof

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6365749B1 (en) 1997-12-04 2002-04-02 Bristol-Myers Squibb Company Process for the preparation of ring-opened epothilone intermediates which are useful for the preparation of epothilone analogs
USRE39356E1 (en) 2000-03-20 2006-10-17 Bristol-Myers Squibb Co. Process for the preparation of epothilone analogs
WO2011153221A1 (en) * 2010-06-01 2011-12-08 Plus Chemicals Sa Solid state forms of ixabepilone
WO2013008091A1 (en) * 2011-07-13 2013-01-17 Xellia Pharmaceuticals Aps Manufacturing of epothilone derivatives and the use thereof

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
BORZILLERI R M ET AL: "A novel application or a Pd(O)-Catalyzed nucleophilic substitution reaction to the regio- and stereoselective synthesis of lactam analogues of the epothilone natural products", JOURNAL OF THE AMERICAN CHEMICAL SOCIETY, ACS PUBLICATIONS, US, vol. 122, 1 January 2000 (2000-01-01), pages 8890 - 8897, XP002173110, ISSN: 0002-7863, DOI: 10.1021/JA001899N *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2015087351A3 (en) * 2013-12-11 2015-12-03 Msn Laboratories Private Limited Process for the preparation of (1s,3s,7s,10r,11s,12s,16r)-7,11-dihydroxy-8,8,10,12,16-pentamethyl-3-[(1e)-1-methyl-2-(2-methyl-4-thiazolyl)ethenyl]-17-oxa-4-azabicyclo[14.1.0]heptadecane-5,9-dione and intermediates thereof

Similar Documents

Publication Publication Date Title
CA2951824C (en) Aminoalkylbenzothiazepine derivatives and uses thereof
WO2018183649A1 (en) Process for the preparation of 6-(cyclopropaneamido)-4-((2-methoxy-3-(1-methyl-1h-1,2,4-triazol-3-yl)phenyl)amino)-n-(methyl-d3)pyridazine-3-carboxamide
CA2950300A1 (en) Synthesis of polycyclic-carbamoylpyridone compounds
WO2007100346A1 (en) Improved process for the preparation of letrozole
WO2014083512A1 (en) Process for preparation of abiraterone acetate
JP2015500325A5 (en)
CA2671816A1 (en) Salts of imidazole-5-carboxylic acid derivatives, a method for preparing same and pharmaceutical compositions comprising same
US20140121384A1 (en) Process for bendamustine hydrochloride
WO2013164102A1 (en) Process for preparation of ixabepilone and intermediates useful in said process.
CN106146419A (en) Xanthine oxidase inhibitor
CN107629001B (en) Synthesis method of anticancer drug lenvatinib
WO2007088558A2 (en) A process for purification of valsartan
CN104860992A (en) Preparation method of high-purity fosfluconazole
US9446141B2 (en) Methods of producing cancer compounds
CN107586288B (en) A kind of purification process of Vonoprazan fumarate
EP2643308B1 (en) Process for the preparation of taurolidine and its intermediates thereof
WO2013008091A1 (en) Manufacturing of epothilone derivatives and the use thereof
JP2019089847A (en) Intermediates and methods for synthesizing calicheamicin derivatives
CN101891686A (en) Synthesizing method of N-beta-alanyl-(tau-methyl) histidine
CN106866560B (en) Lesinurad synthesis method
RU2435761C2 (en) Salts of 2'-(1h-tetrazol-5-yl)-1 and 1'-biphenyl-4-carboxaldehyde with metals
CN109305992A (en) A kind of preparation method of azacitidine
US10927133B2 (en) Process for the preparation of ixazomib citrate
WO2017134087A1 (en) Steroidic calixarene compounds, their synthesis and use for extraction, solubilization and/or stabilization of native and functional membrane proteins
CN110143947B (en) Preparation method of ceritinib analogue

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 13700669

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 13700669

Country of ref document: EP

Kind code of ref document: A1